Summary
Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were >65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR+PR) of 86% (CR 29%) and 66% (CR 17%) were seen in patients with limited and extensive disease, respectively. Time to relapse was short in those responding (4–4.5 months), and most responders required additional treatments. The overall toxicity was minimal and patient compliance was high. This combination is useful for the palliative treatment of small cell lung cancer when aggressive chemotherapy is inappropriate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aisner J, Whitacre M, Van Echo DA, Wesley M, Wiemik PM (1982) Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer. Cancer Chemother Pharmacol 7:187
Aisner J, Alberts P, Bitram J, Cornis R, Daniels J, Hansen H, Ikegami M, Smyth J (1983) Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer Workshop. Cancer Treat Rep 67:37
Burn FA, Cohen MM, Ohda DC, Shacney SE, Minna JD (1977) Commentary: Advances in small cell bronchogenic carcinoma. Cancer Treat Rep 61:333
Grego FA, Chardson RL, Snell JN, Stroup SL, Oldham RK (1979) Small cell lung cancer: complete remission and improved survival. Am J Med 66:625
Hansen HH, Roth M (1979) Lung Cancer: In: Cancer chemotherapy. Excerpta Medica, Amsterdam Oxford, p 267
Hansen HH, Selawry OS, Simon R, Carr DT, Van Wyk CE, Tucker RD, Sealy R (1976) Combination chemotherapy of advanced lung cancer. Cancer 38:2201
Kessinger A, Foley JF, Lemon HM (1983) Can maximum benefit be achieved with lower dosages and less toxicity in the chemotherapeutic management of small cell lung cancer? Proc ASCO 2:C274
Maltson K, Holsti LR, Salmo M, Saastamsinen M, Ahledst S, Holsti P (1980) Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: preliminary results. Cancer Treat Rev [Supp] 7:65
Minna JD, Higgins GA, Glatstein EJ (1982) Cancer of the lung: In: Cancer: Principles and practice of oncology. Lippincott, Philadelphia Toronto, p 396
Natale RB, Gralla RJ, Wittes RE, Golbey RB, Young CW (1980) Vindesine chemotherapy in lung cancer. Cancer Treat Rev [Suppl] 7:59
Osterling K, Ihde DC, Eltinger DS, Gralla RJ, Karrer K, Krauss S, Maruer LH, Porth M, Sorenson S, Vincent R (1983) Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep 677:3
Weiss RB (1978) Small cell carcinoma of the lung: therapeutic management. Ann Intern Med 88:522
WHO (1979) Handbook for reporting the results of cancer treatment. WHO, Geneva (Offset Publication no. 48)
Young CW (1980) Vindesine trials at Memorial Sloan-Kettering Cancer Centre. Cancer Treat Rev [Suppl] 7:53
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allan, S.G., Gregor, A., Cornbleet, M.A. et al. Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother. Pharmacol. 13, 106–108 (1984). https://doi.org/10.1007/BF00257124
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257124